GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (OTCPK:MLLNF) » Definitions » Valuation Rank

Malin (MLLNF) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is Malin Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Malin Valuation Rank Related Terms

Thank you for viewing the detailed overview of Malin's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Malin Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (OTCPK:MLLNF) » Definitions » Valuation Rank
Comparable Companies
ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692 SZSE:000538 BOM:500087 ITCI VTRS TSE:4507 NBIX NSE:TORNTPHARM SHSE:688506 BOM:543904 BOM:500124
Traded in Other Exchanges
MLC:Ireland
Address
50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Website
http://www.malinplc.com
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.